27.08.2012 - The German antibody specialist Wilex AG has completed a capital increase to strengthen its capital base. The biotech sold 6.5 million new shares at a price of €3.70.
However not all the shares were sold for cash. As contribution in kind, the company’s largest shareholder Dievini Hopp BioTech Holding GmbH, the investment vehicle of the billionaire and SAP founder Dietmar Hopp, converted an existing loan granted to Wilex amounting to approximately €7.8m to 2.1 million new shares. This represents 32.5% of the total volume of the capital increase.This reduces Wilex' financial liabilities without adversely affecting cash reserves. Finally, Wilex receives gross proceeds of around €16.1m from the cash portion of the transaction. The company now owns about €24m in cash. Wilex runs a number of early and mid-stage clinical trials. However, the most important one is the phase III with the kidney cancer antibody Rencarex. Results for the test with the anti-EpCAM-mAb are anticipated for the end of this year. Rencarex is partnered with Prometheus Labs in the US.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.